These findings suggest that an altered function of CUG-BP1 plays a pivotal role in the pathogenic process of skeletal muscle atrophy, and CUG-BP1 can be served as a target for clinical intervention of neurogenic skeletal muscle atrophy. This evidence concerns the gene CELF1 and muscular atrophy.